The complexities in system building strategies — The case of personalized cancer medicines in England
暂无分享,去创建一个
[1] Stefan Kuhlmann,et al. Functions of innovation systems: A new approach for analysing technological change , 2007 .
[2] R. Tuma. Trastuzumab trials steal show at ASCO meeting. , 2005, Journal of the National Cancer Institute.
[3] S Senan,et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] Staffan Jacobsson,et al. Innovation systems: analytical and methodological issues , 2002 .
[5] Björn A. Sandén,et al. A framework for analysis of multi-mode interaction among technologies with examples from the history of alternative transport fuels in Sweden , 2011 .
[6] Staffan Jacobsson,et al. Transforming the Energy Sector : The evolution of technological systems in renewable energy technology , 2004 .
[7] Ozgur Dedehayir,et al. Dynamics of reverse salience as technological performance gap: An empirical study of the personal computer technology system , 2008 .
[8] D. B. Montgomery,et al. First‐mover advantages , 1988 .
[9] W. Boon. Demanding Dynamics - Demand articulation of intermediary organisations in emerging pharmaceutical innovations , 2003 .
[10] Wim Turkenburg,et al. Accelerating the deployment of carbon capture and storage technologies by strengthening the innovation system , 2010 .
[11] Neil Rubens,et al. A Network Analysis of Investment Firms as Resource Routers in Chinese Innovation Ecosystem , 2011, J. Softw..
[12] T. Hellevik,et al. Radiotherapy and the Tumor Stroma: The Importance of Dose and Fractionation , 2014, Front. Oncol..
[13] Lars Coenen,et al. Sustainability transitions in the making: A closer look at actors, strategies and resources , 2012 .
[14] Ron Adner,et al. Value Creation in Innovation Ecosystems: How the Structure of Technological Interdependence Affects Firm Performance in New Technology Generations , 2009 .
[15] Marko P. Hekkert,et al. Innovation Studies Utrecht ( ISU ) Working Paper Series Understanding the build-up of a Technological Innovation System around Hydrogen and Fuel Cell Technologies , 2009 .
[16] Staffan Jacobsson,et al. Analyzing the functional dynamics of technological innovation systems: A scheme of analysis , 2008 .
[17] M. Boysen,et al. Erlotinib for the treatment of non-small-cell lung cancer. , 2009, The Lancet. Oncology.
[18] Charles Edquist,et al. Systems of innovation perspectives and challenges , 2004 .
[19] Staffan Jacobsson,et al. The emergence and troubled growth of a 'biopower' innovation system in Sweden , 2008 .
[20] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[21] B. Truffer,et al. Sustainability transitions: An emerging field of research and its prospects , 2012 .
[22] C. Freeman. Technology policy and economic performance : lessons from Japan , 1987 .
[23] R. Laing,et al. HER2 testing in the UK: consensus from a national consultation , 2007, Journal of Clinical Pathology.
[24] Jochen Markard,et al. Technological innovation systems and the multi-level perspective: Towards an integrated framework , 2008 .
[25] Bengt-Åke Lundvall,et al. National Systems of Innovation: towards a theory of innovation and interactive learning London: Pint , 1995 .
[26] C Proudlove,et al. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. , 2010, Health technology assessment.
[27] Ron Adner. Match your innovation strategy to your innovation ecosystem. , 2006, Harvard business review.
[28] James F. Moore. The Death of Competition: Leadership and Strategy in the Age of Business Ecosystems , 1996 .
[29] Susanne Durst,et al. Success factors of innovation ecosystems - Initial insights from a literature review , 2013 .
[30] Staffan Jacobsson,et al. In Search of Useful Public Policies — Key Lessons and Issues for Policy Makers , 1997 .
[31] J. Islas,et al. Getting round the lock-in in electricity generating systems: the example of the gas turbine , 1997 .
[32] D. Miles,et al. Safety and efficacy of the combination of trastuzumab with docetaxel for HER2‐positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK , 2004, International journal of clinical practice.
[33] S. Nambisan,et al. Entrepreneurship and strategic thinking in business ecosystems , 2012 .
[34] Jane Fridlyand,et al. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics , 2013, Nature Reviews Drug Discovery.
[35] Glyn Elwyn,et al. Putting patients first , 2012, BMJ : British Medical Journal.
[36] J. Ashton-Chess,et al. Market access challenges in the EU for high medical value diagnostic tests. , 2011, Personalized medicine.
[37] F. Geels. From sectoral systems of innovation to socio-technical systems: Insights about dynamics and change from sociology and institutional theory , 2004 .
[38] R.A.A. Suurs,et al. Motors of sustainable innovation : Towards a theory on the dynamics of technological innovation systems , 2009 .
[39] I. Ellis,et al. Recommendations for HER2 testing in the UK , 2000, Journal of clinical pathology.
[40] Charles Edquist,et al. Systems of Innovation Approaches - Their Emergence and Characteristics , 2013 .
[41] Michael E. Holmes,et al. Organizational Change and Innovation Processes: Theory and Methods for Research , 2000 .
[42] C. Edquist. Systems of Innovation: Technologies, Institutions and Organizations , 1997 .
[43] D De Ruysscher,et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[44] Mariano Provencio,et al. Screening for epidermal growth factor receptor mutations in lung cancer. , 2009, The New England journal of medicine.
[45] Cristina Chaminade,et al. Rationales for Public Policy Intervention in the Innovation Process: Systems of Innovation Approach , 2010 .
[46] Marshall Scott Poole,et al. Methods for Studying Innovation Development in the Minnesota Innovation Research Program , 1990 .
[47] Jochen Markard,et al. Creating and shaping innovation systems: Formal networks in the innovation system for stationary fuel cells in Germany , 2011 .
[48] M. Hekkert,et al. Innovation Studies Utrecht ( ISU ) Working Paper Series Systemic instruments for systemic innovation problems : a framework for policy makers and innovation scholars , 2011 .
[49] F. Olleros. Emerging Industries and the Burnout of Pioneers , 1986 .
[50] H. Rohracher,et al. Legitimizing research, technology and innovation policies for transformative change , 2012 .
[51] Jochen Markard,et al. Actor-oriented analysis of innovation systems: exploring micro–meso level linkages in the case of stationary fuel cells , 2008, Technol. Anal. Strateg. Manag..
[52] Raghu Garud,et al. Institutional Entrepreneurship as Embedded Agency: An Introduction to the Special Issue , 2007 .
[53] J. F. Moore,et al. Predators and prey: a new ecology of competition. , 1993, Harvard business review.
[54] F. Geels. Technological transitions as evolutionary reconfiguration processes: a multi-level perspective and a case-study , 2002 .
[55] B. Carlsson,et al. On the nature, function and composition of technological systems , 1991 .
[56] Staffan Jacobsson,et al. Opportunities for and limits to Academics as System builders—The case of realizing the potential of gasified biomass in Austria , 2009 .
[57] J. T. Jørgensen,et al. Companion Diagnostics for Targeted Cancer Drugs – Clinical and Regulatory Aspects , 2014, Front. Oncol..
[58] R. Comis,et al. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer. , 2005, The oncologist.
[59] Jochen Markard,et al. Context matters: How existing sectors and competing technologies affect the prospects of the Swiss Bio-SNG innovation system , 2011 .
[60] Marko P. Hekkert,et al. Explaining the failure of the Dutch innovation system for biomass digestion : A functional analysis , 2007 .
[61] M. Hekkert,et al. Networks and network resources in technological innovation systems: Towards a conceptual framework for system building , 2012 .
[62] A. Hedgecoe,et al. The Politics of Personalised Medicine: Pharmacogenetics in the Clinic , 2004 .